Coen Stacy Ann 4
4 · ImmunoGen, Inc. · Filed Feb 6, 2024
Insider Transaction Report
Form 4
ImmunoGen, Inc.IMGN
Coen Stacy Ann
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2024-02-02+14,350→ 77,857 total - Sale
Common Stock
2024-02-05$29.30/sh−4,583$134,282→ 73,274 total - Exercise/Conversion
Restricted Stock Unit
2024-02-02−14,350→ 28,700 totalExercise: $0.00→ Common Stock (14,350 underlying)
Footnotes (3)
- [F1]Effected pursuant to a trading plan adopted on June 15, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- [F3]The RSUs were awarded on 2/3/2023 and vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.